

# **Efficacy of Atorvastatin in Prevention of Contrast induced Nephropathy in Patients Undergoing Coronary Angiography**

Thesis

*Submitted for Partial Fulfillment of Master Degree in  
Intensive Care Medicine*

By

***Amira Mohamed Gaber Mahmoud***  
*M.B.B.Ch*

Under Supervision of

**Prof. Dr./ Ayman Mokhtar Kamaly**

*Professor of Anesthesia, Intensive Care and Pain Management  
Faculty of Medicine, Ain Shams University*

**Dr./ Ghada Mohamed Samir**

*Assistant Professor of Anesthesia, Intensive Care and Pain Management  
Faculty of Medicine, Ain Shams University*

**Dr./ Hany Magdy Fahim**

*Lecturer of Anesthesia, Intensive Care and Pain Management  
Faculty of Medicine, Ain Shams University*

Faculty of Medicine  
Ain Shams University

**2020**



سورة البقرة الآية: ٣٢

# Acknowledgment

All praise is to **Allah** and all thanks. **Allah** has guided and enabled me by his mercy to fulfill this thesis, which I hope to be beneficial for people.





I would like to express my deepest gratitude and sincere appreciation to **Prof. Dr./ Ayman Mokhtar Kamaly** Professor of Anesthesia, Intensive Care and Pain Management Faculty of Medicine, Ain Shams University for his continuous encouragement, his kind support and appreciated suggestions that guided me to accomplish this work.

I am also grateful to **Dr./ Ghada Mohamed Samir** Assistant Professor of Anesthesia, Intensive Care and Pain Management Faculty of Medicine Ain Shams University who freely gave his time, effort and experience along with continuous guidance through out this work.

I am also grateful to **Dr./ Hany Magdy Fahim**, Lecturer of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University who freely gave his time, effort and experience along with continuous guidance through out this work.

**Amira Mohamed**

# *List of Contents*

Title	Page No.
List of Tables .....	i
List of Figures .....	ii
List of Abbreviations .....	iii
Introduction .....	i
Aim of the Work .....	3
Review of Literature	
 Contrast-Induced Nephropathy .....	4
 Pathogenesis of Contrast Nephropathy .....	6
 Prophylactic and Therapeutic Measures for Contrast Nephropathy .....	32
 Statins Use in Contrast Nephropathy .....	40
Patients and Methods .....	47
Results .....	52
Discussion .....	61
Summary .....	69
Recommendations .....	72
References .....	73
Arabic Summary .....	

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Shows definitions of contrast nephropathy .....	5
<b>Table (2):</b>	Shows severity grading of contrast nephropathy .....	6
<b>Table (3):</b>	Shows comparison between different contrast media.....	12
<b>Table (4):</b>	Shows guidelines to prevent contrast nephropathy.....	12
<b>Table (5):</b>	Shows recommendations of contrast use to avoid contrast nephropathy.....	24
<b>Table (6):</b>	Shows risk factors for contrast nephropathy.....	25
<b>Table (7):</b>	Shows risk score of contrast nephropathy .....	26
<b>Table (8):</b>	Shows procedural risk score of contrast nephropathy .....	26
<b>Table (9):</b>	Shows descriptive clinical and laboratory data of group 2. Data expressed as Mean + Standard deviation.....	52
<b>Table (10):</b>	Shows comparison between the two groups as regard demographic data .....	53
<b>Table (11):</b>	Shows comparison between the two groups as regard clinical and laboratory data .....	54
<b>Table (12):</b>	Shows effect of different parameters on prevalence of contrast nephropathy in both groups.....	55
<b>Table (13):</b>	Shows correlation between different clinical and laboratory parameters.....	56

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Shows correlation between age and 72 h- Serum creat. (mg\dl). There was a highly significant positive correlation.....	57
<b>Figure (2):</b>	Shows correlation between serum cholesterol and 72 h- Serum creat. (mg\dl).....	57
<b>Figure (3):</b>	Shows correlation between serum triglycerides and 72 h- Serum creat. (mg\dl). There was a highly significant positive correlation.....	57
<b>Figure (4):</b>	Shows correlation between LDL and 72 h- Serum creat.(mg\dl). There was a highly significant positive correlation.....	58
<b>Figure (5):</b>	Shows correlation between HDL and 72 h- Serum creat.(mg\dl). There was a highly significant negative correlation.....	58
<b>Figure (6):</b>	Shows correlation between FBS and 72 h- Serum creat.(mg\dl). There was a highly significant positive correlation.....	58
<b>Figure (7):</b>	Shows correlation between serum uric acid and 72 h- Serum creat.(mg\dl). There was a highly significant positive correlation.....	59
<b>Figure (8):</b>	Shows correlation between Hb% and 72 h- Serum creat ....	59
<b>Figure (9):</b>	Shows correlation between dose of contrast dye and 72 h- Serum creat.(mg\dl). There was a highly significant positive correlation.....	59
<b>Figure (10):</b>	Shows correlation between baseline serum creatinine and delta GFR. There was a highly significant negative correlation.....	60

# *List of Abbreviations*

<b>Abb.</b>	<b>Full term</b>
<i>AKI</i> .....	<i>Acute Kidney Injury</i>
<i>AKIN</i> .....	<i>Acute Kidney Injury Network</i>
<i>ATN</i> .....	<i>Atorvastatin</i>
<i>CA</i> .....	<i>Coronary Angiography</i>
<i>ESC</i> .....	<i>Europeans society of cardiology</i>
<i>CIN</i> .....	<i>Contrast-Induced Nephropathy</i>
<i>CRP</i> .....	<i>C-Reactive Protein</i>
<i>GMSC</i> .....	<i>CM Safety Committee</i>
<i>HOCM</i> .....	<i>High-Osmolar Contrast Media</i>
<i>ICAM-1</i> .....	<i>Intracellular Cell Adhesion Molecule 1</i>
<i>ICM</i> .....	<i>Iodinated Contrast Media</i>
<i>IL-1<math>\beta</math></i> .....	<i>Interferon-1 Beta</i>
<i>IL6</i> .....	<i>Interleukin 6</i>
<i>LVEF</i> .....	<i>Left Ventricular Ejection Fraction</i>
<i>MHC</i> .....	<i>Major Histocompatibility Complex</i>
<i>MM</i> .....	<i>Multiple Myeloma</i>
<i>NAC</i> .....	<i>N-acetylcysteine</i>
<i>NFG</i> .....	<i>Normal Fasting Glucose</i>
<i>NGAL</i> .....	<i>Neutrophil Gelatinase-Associated Lipocalin-2</i>
<i>NO</i> .....	<i>Nitric Oxide</i>
<i>PCI</i> .....	<i>Percutaneous Coronary Intervention</i>
<i>PGE2</i> .....	<i>Prostaglandin E2</i>
<i>pPCI</i> .....	<i>Primary Percutaneous Coronary Intervention</i>
<i>ROS</i> .....	<i>Reactive Oxygen Species</i>
<i>SCr</i> .....	<i>Serum Creatinine</i>
<i>STEMI</i> .....	<i>ST Elevation Myocardial Infarction</i>
<i>VCAM-1</i> .....	<i>Vascular Cell Adhesion Molecule</i>
<i><math>\beta</math>2M</i> .....	<i>Beta-2Microglobulin</i>
<i>ACR</i> .....	<i>American Association of Radiology</i>

# INTRODUCTION

The use of radiocontrast media has increased greatly from the past decades for diagnostic radiography and interventional procedures and it is estimated that approximately 60 million people in the world are used radiocontrast media each year (*Assareh et al., 2016*).

On the other hand, the administration of radiocontrast media may lead to acute kidney injury (AKI) that begins soon after the contrast is administered. Contrast-induced nephropathy (CIN) is defined as the impairment of renal function measured as either a 25% increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44  $\mu$ mol/L) increase in absolute SCr value within 48-72 hours after intravenous contrast administration (*KDIGO et al., 2016*).

Contrast-induced nephropathy (CIN) is of concern after the use of radiocontrast media for coronary angiography (CAG) and percutaneous coronary intervention (PCI). Many studies has studied the incidence of CIN and its risk factors in patients undergoing CAG (*Kumar et al., 2016*).

Interaction between inflammatory mechanisms and oxidative stress are involved in the pathogenesis of CIN (*Hossain et al., 2016*).



Statins may decrease inflammation and improve endothelial function, decreasing expression of endothelial adhesion molecules, and increasing NO bioavailability (*Syed et al., 2016*).

## **AIM OF THE WORK**

The aim of this study was to evaluate the efficacy of atorvastatin (ATN) 80 mg in the prevention of CIN in patients undergoing angiography.

# CONTRAST-INDUCED NEPHROPATHY

The European Society of Urogenital Radiology defines kidney injury as CIN (well received by the radiological community) if there is an increase in serum creatinine of 0.5mg/dL or > 25% of the baseline within 72 hours of contrast administration (3, 5-8) in the absence of an alternative etiology (*Wichmann et al., 2015*).

Definition of contrast induced nephropathy is not uniform, with the used criteria showing discrepancies. According to the Acute Kidney Injury Network (AKIN), CIAKI is defined as an increase in serum creatinine > 0.3mg/dL or > 50% of the baseline within 48 hours after the administration of intravenous contrast (*Moura et al., 2017*).

Contrast-induced nephropathy (CIN) is defined as the impairment of renal function measured as either a 25% increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 µmol/L) increase in absolute SCr value-within 48-72 hours after intravenous contrast administration (*van der Molen et al., 2018*).

**Table (1):** Shows definitions of contrast nephropathy (*Moura et al., 2017*)

Criteria		Definition	
CIN		Increase in sérum creatinine of 0.5mg/dL or > 25% of the baseline within 72 hours of contrast administration	
CIAKI		Increase in sérum creatinine > 0.3mg/dL or > 50% of the baseline within 48 hours after administration of intravenous contrast	
KDIGO staging	1	1.5 X	Increase in sérum creatinine level
	2	2 X	
	3	3 X	

Despite technological advances, CIN remains responsible for a third of all hospital-acquired acute kidney injury (AKI) and affects between 1% and 2% of the general population and up to 50% of high-risk subgroups following coronary angiography (CA) or percutaneous coronary intervention (PCI) (*Mehran et al., 2006*).

Contrast-induced nephropathy (CIN) is a common complication of primary percutaneous coronary intervention (pPCI) and is associated with high mortality and morbidity and long hospital stay in patients with ST elevation myocardial infarction (STEMI) (*Rencuzogullari et al., 2018*).

**Table (2):** Shows severity grading of contrast nephropathy (*Harjai et al., 2013*)

CIN grade	Change in serum creatinine	6 month outcomes
Grade 0	SCr increase <25% and <0.5 mg/dL above baseline	MACE 12.4% Mortality 10.2%
Grade 1	SCr increase $\geq$ 25% and <0.5 mg/dL above baseline	MACE 19.4% Mortality 10.4%
Grade 2	SCr increase $\geq$ 0.5 mg/dL above baseline	MACE 28.6% Mortality 40.9%

CIN, contrast-induced nephropathy; MACE, major adverse cardiovascular event; SCr, serum creatinine.

# PATHOGENESIS OF CONTRAST NEPHROPATHY

In spite of an unclear understanding of the mechanisms underlying CIN, tubular toxicity and endothelial vasoconstriction, together with reactive oxygen species (ROS), are implicated in the pathogenesis of CIN (*Seeliger et al., 2012*).

## **Contrast induced tubular toxicity:**

Iodinated contrast media directly injures the renal tubular epithelium by producing ROS radicals that cause intra-renal vasoconstriction leading to ischaemia and death of tubular cells. Contrast media is characterized by high osmolality and increased viscosity (thickness), even the iso-osmolar contrast media is extremely hyperviscous compared to plasma (*Chao et al., 2013*). Increased hyperviscosity and osmolality cause direct damage to renal tubules and with increased intratubular pressure consequently lead to compromised renal blood flow and decreased glomerular filtration rate. Previous studies have reported a positive association between contrast media administration and tubular cell vacuolation (*Mitchell et al., 2010*).

### **a. Endothelial dysfunction in CIN:**

An imbalance of vasoconstrictors and vasodilators plays a critical role in mediating CIN. Contrast media suppresses intra-renal vasodilators i.e. nitric oxide (NO) and prostaglandin E2 (PGE2) and increases intra-renal vasoconstrictors that decrease blood flow to the renal medulla leading to hypoxic ischaemia, production of ROS and death of tubular cells (*Azzalini et al., 2016*).

Vasoconstriction in CIN is mediated by adenosine and endothelins acting on A1 and E1 receptors respectively. Endothelin receptor stimulation is associated with decreased GFR (*Deng et al., 2015*).

### **b. Medullary hypoxia and CIN:**

In CIN, the presence of hypoxia in the outer medulla of the kidney is essential in the pathogenesis of CIN (*Geenen et al., 2013*). Following contrast administration, the outer medullary renal blood flow exhibits two phases; a brief period characterized by increased flow that is later followed by an almost 25% sustained decrease in renal blood flow that ultimately impacts poorly on oxygen delivery to the medulla. The partial pressure of oxygen decreases to as low as 10-15 mmHg post contrast administration (*Seeliger et al., 2012*).